Bluejay Diagnostics (BJDX)
Market Price (4/25/2026): $1.87 | Market Cap: $1.1 MilSector: Health Care | Industry: Life Sciences Tools & Services
Bluejay Diagnostics (BJDX)
Market Price (4/25/2026): $1.87Market Cap: $1.1 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -439% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns2Y Excs Rtn is -144%, 3Y Excs Rtn is -172% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.0 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -600% High stock price volatilityVol 12M is 135% Key risksBJDX key risks include [1] a critical funding shortfall that has created a going concern risk and delayed clinical trials, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -439% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -144%, 3Y Excs Rtn is -172% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.0 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -600% |
| High stock price volatilityVol 12M is 135% |
| Key risksBJDX key risks include [1] a critical funding shortfall that has created a going concern risk and delayed clinical trials, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Negative Market Reaction to 1-for-4 Reverse Stock Split. Bluejay Diagnostics implemented a 1-for-4 reverse stock split on January 29, 2026, a corporate action often perceived by the market as a sign of underlying financial distress. This event led to an immediate 3.87% decline in shares following its announcement on January 27, 2026.
2. Sustained Lack of Profitability and Consistent Earnings Misses. The company has demonstrated a prolonged lack of profitability, reporting a net loss of approximately -$6.8 million for the fiscal year 2025. Bluejay Diagnostics consistently missed EPS estimates for six consecutive quarters, with the Q3 2025 actual EPS being -$4.04 against an estimated $0.00.
Show more
Stock Movement Drivers
Fundamental Drivers
The -28.9% change in BJDX stock from 12/31/2025 to 4/24/2026 was primarily driven by a -34.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.67 | 1.90 | -28.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -34.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| BJDX | -28.9% | |
| Market (SPY) | 4.2% | 26.7% |
| Sector (XLV) | -6.9% | 14.8% |
Fundamental Drivers
The -68.8% change in BJDX stock from 9/30/2025 to 4/24/2026 was primarily driven by a -42.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.08 | 1.90 | -68.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -42.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| BJDX | -68.8% | |
| Market (SPY) | 7.0% | 7.9% |
| Sector (XLV) | 4.0% | 5.9% |
Fundamental Drivers
The -87.3% change in BJDX stock from 3/31/2025 to 4/24/2026 was primarily driven by a -77.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.92 | 1.90 | -87.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 1 | -77.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/24/2026| Return | Correlation | |
|---|---|---|
| BJDX | -87.3% | |
| Market (SPY) | 28.1% | 1.8% |
| Sector (XLV) | 0.1% | -0.0% |
Fundamental Drivers
The -100.0% change in BJDX stock from 3/31/2023 to 4/24/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4242026 | Change |
|---|---|---|---|
| Stock Price ($) | 13094.40 | 1.90 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | |
| P/S Multiple | 33.2 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 0 | 1 | -99.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/24/2026| Return | Correlation | |
|---|---|---|
| BJDX | -100.0% | |
| Market (SPY) | 79.8% | 2.9% |
| Sector (XLV) | 16.6% | 3.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BJDX Return | -52% | -85% | -84% | -99% | -86% | -27% | -100% |
| Peers Return | 3% | -29% | -3% | -21% | -23% | -25% | -67% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 89% |
Monthly Win Rates [3] | |||||||
| BJDX Win Rate | 0% | 33% | 33% | 25% | 33% | 50% | |
| Peers Win Rate | 55% | 40% | 43% | 42% | 43% | 25% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BJDX Max Drawdown | -56% | -87% | -84% | -99% | -86% | -34% | |
| Peers Max Drawdown | -19% | -47% | -31% | -31% | -36% | -31% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: QDEL, OSUR, VNRX, ABT, DHR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/24/2026 (YTD)
How Low Can It Go
| Event | BJDX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.9% | -25.4% |
| % Gain to Breakeven | 8878.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to QDEL, OSUR, VNRX, ABT, DHR
In The Past
Bluejay Diagnostics's stock fell -98.9% during the 2022 Inflation Shock from a high on 11/10/2021. A -98.9% loss requires a 8878.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bluejay Diagnostics (BJDX)
AI Analysis | Feedback
Here are a few brief analogies for Bluejay Diagnostics:
- Like a smaller, focused **Abbott Laboratories** for specialized diagnostic tests.
- A startup developing innovative diagnostic platforms, similar to a mini-**Roche Diagnostics**.
AI Analysis | Feedback
- Symphony platform: A technology platform comprising an immuno-analyzer and a cartridge library, designed for blood processing, biomarker isolation, and immunoassay preparation.
- ALLEREYE diagnostic test: A point-of-care (POC) device used for the diagnosis of allergic conjunctivitis.
- Diagnostic Biomarkers: Specific markers, such as hsTNT/I and NT-proBNP, developed for the detection of diseases like myocardial injury and cardiac heart failure.
AI Analysis | Feedback
Based on the provided background information, the specific names of Bluejay Diagnostics' major customers are not identified.
However, given that Bluejay Diagnostics, Inc. develops and markets diagnostic products and platforms (such as the Symphony platform, ALLEREYE diagnostic test, and various biomarkers) for triage, diagnosis, and monitoring of disease progression, the company sells primarily to other companies and healthcare institutions (B2B). Its customer base would typically include:
- Hospitals and Healthcare Systems: For use in their diagnostic laboratories, emergency departments, and other clinical settings to aid in patient diagnosis and monitoring.
- Clinics and Physician Offices: Especially for point-of-care (POC) diagnostic devices like the ALLEREYE test, enabling rapid, in-office testing and diagnosis.
- Reference Laboratories: Institutions that perform specialized diagnostic testing services for a broad range of healthcare providers, utilizing advanced platforms and biomarker detection.
AI Analysis | Feedback
```html- Toray Industries, Inc. (TYO: 3402)
AI Analysis | Feedback
Neil Dey, President, Chief Executive Officer, and Principal Financial and Accounting Officer
Mr. Dey co-founded Bluejay Diagnostics in 2015. Before that, he co-founded Lana Management & Business Research International (LMBRI) in 2007, a management consulting company that specialized in the launch and marketing of medical products across the US, Japan, and EU. During his eight years at LMBRI, he consulted with companies such as Toray Industries, Hitachi Chemicals, and Fuji Chemicals. Prior executive positions include Vice President of Business Development and Market for Definines, AG (acquired by AstraZeneca) from 2005 to 2007. From 2001 to 2005, he was Head of Business Development, Western US, at IMPATH, Inc., where he was involved in introducing Her2neu Diagnostics. He also served as Chief Business Officer at Genmethrax, Inc., and held management roles in technology licensing at Thomas Jefferson Medical University and Ciba Geigy (Novartis). As of April 2, 2024, Mr. Dey also assumed the responsibilities of principal financial and accounting officer for Bluejay Diagnostics.
Kevin Vance, CCO
Les DeLuca, VP of Operations
Diane Palermo, Quality Assurance Manager
Amit K. Roy, Principal Scientist
AI Analysis | Feedback
-
Financial Health and Going Concern Uncertainty
Bluejay Diagnostics faces significant financial challenges, having incurred substantial losses since its inception and lacking current product revenue. The company anticipates needing to raise at least $20 million in additional capital by the end of fiscal year 2027 to continue operations, with a risk of exhausting available cash as early as the third quarter of 2026 without further funding. This situation explicitly raises substantial doubt about the company's ability to continue as a going concern.
-
Product Development, Clinical Trial, and Regulatory Approval Risk
The company's future success heavily depends on the successful development, clinical validation, and regulatory approval of its Symphony platform and lead product candidate, the IL-6 test for sepsis. The SYMON-II pivotal clinical trial is currently underway, with the goal of submitting a 510(k) regulatory application to the FDA in 2027. However, there is no guarantee that the company will receive FDA clearance. The company has not received any FDA approvals for its therapies in the last two years, and delays in clinical trials due to financial constraints have been noted.
-
Reliance on Third-Party Agreements and Manufacturing
Bluejay Diagnostics is dependent on single suppliers for critical components and manufacturing processes. Specifically, the company relies on Toray Industries, Inc. for its core technology, including protein detection chips/cartridges, and on Sanyoseiko for cartridge manufacturing. The potential termination of the license agreement with Toray or challenges in redeveloping and validating disposable cartridges represent significant operational and supply chain risks that could severely impact the company's ability to commercialize its products.
AI Analysis | Feedback
The clear emerging threat for Bluejay Diagnostics (BJDX) is the rapid advancement and adoption of next-generation diagnostic technologies, such as CRISPR-based diagnostics, highly sensitive microfluidic systems, and non-invasive biosensors. These emerging technologies offer the potential for significantly superior speed, accuracy, multiplexing capabilities, and cost-effectiveness, which could render traditional fluorescence immunoassay platforms like BJDX's Symphony and its protein detection chips less competitive or potentially obsolete before they achieve widespread market penetration.
AI Analysis | Feedback
Bluejay Diagnostics (BJDX) develops and markets several diagnostic products and biomarkers. The addressable markets for these products are as follows:
ALLEREYE Diagnostic Test (for Allergic Conjunctivitis)
- The global allergic conjunctivitis market was valued at USD 3.37 billion in 2025 and is projected to reach USD 5.58 billion by 2034.
- North America represented the largest share of this market, valued at USD 1.65 billion in 2025 and USD 1.74 billion in 2026. The U.S. market alone is projected to reach USD 1.64 billion by 2026.
- More broadly, the global conjunctivitis market, which includes allergic, bacterial, and viral forms, was valued at USD 4.8 billion in 2023 and is expected to grow to USD 7.2 billion by 2033. Allergic conjunctivitis accounted for the largest share within this market in 2023.
- The allergic conjunctivitis segment of the conjunctivitis treatment market is expected to demonstrate the fastest growth rate, at 21.7% from 2025 to 2032.
- The global allergy point-of-care testing market, which includes devices like ALLEREYE, is forecasted to reach USD 1.6 billion in 2026 and expand to USD 4.2 billion by 2036.
Biomarkers for Myocardial Injury (hsTNT/I - high-sensitivity Troponin I)
- The global high-sensitivity Troponin I testing market size was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.8 billion by 2033.
- North America currently holds the largest share, over 38%, of the global High-Sensitivity Troponin I Testing market.
- The global cardiac troponin market size, which includes Troponin I, is estimated at USD 4.30 billion in 2025 and is predicted to increase to approximately USD 11.44 billion by 2035.
- Troponin I specifically dominated the cardiac troponin market in 2023 with a 58.2% market share.
- The broader global heart attack diagnostics market, which includes tests for myocardial injury, was valued at USD 11.18 billion in 2023 and is projected to reach around USD 25.05 billion by 2033. Blood tests, including high-sensitivity troponin, accounted for 41.02% of global revenue in 2025 within this market.
Biomarkers for Cardiac Heart Failure (NT-proBNP)
- The global NT-proBNP Test Kit market size is expected to grow from USD 1.2 billion in 2023 to a projected USD 2.5 billion by 2032.
- North America holds the largest share, approximately 45%, of the global BNP and NT-proBNP testing market.
- The global BNP and NT-proBNP market was valued at USD 1.92 billion in 2024 and is projected to reach USD 2.91 billion by 2030.
- The global BNP & NT-proBNP diagnostics market grew from USD 1.36 billion in 2025 to USD 1.57 billion in 2026 and is projected to reach USD 3.62 billion by 2032.
- The global market for BNP and NT-proBNP was valued at USD 1.1 billion in 2021 and is projected to reach USD 3.4 billion by 2031.
- The heart failure point-of-care (POC) and low-oxygen concentration (LOC) devices market, relevant to diagnostic platforms, was valued at approximately USD 91.7 million in 2023 and is estimated to grow at a 16.4% CAGR from 2024 to 2032. The U.S. heart failure POC and LOC devices market is also anticipated to grow at a 16% CAGR.
AI Analysis | Feedback
For Bluejay Diagnostics (NASDAQ: BJDX), expected drivers of future revenue growth over the next 2-3 years primarily revolve around the successful development, regulatory approval, and commercialization of its core diagnostic platform and associated tests.
-
Commercialization of the Symphony Platform and its Lead IL-6 Sepsis Test: The primary driver of future revenue growth is the successful regulatory clearance and subsequent market introduction of the Symphony platform, beginning with its lead product candidate, an Interleukin-6 (IL-6) test for sepsis risk assessment and critical care decision-making. Bluejay Diagnostics is actively advancing its SYMON™ II clinical study to generate data to support its regulatory strategy for this test. Once approved, the Symphony System, designed as a rapid, near-patient testing solution, is expected to be a key revenue generator in hospital and long-term acute care settings.
-
Scaling Manufacturing and Establishing a Robust Supply Chain: To support the commercialization efforts, Bluejay Diagnostics is focused on scaling up its manufacturing capabilities and strengthening its supply chain. The company has expanded its strategic partnership with SanyoSeiko Co., Ltd. for end-to-end support, including manufacturing redevelopment for analyzers and cartridges, raw material sourcing, and quality control. This readiness in production capacity and supply chain robustness is crucial for meeting anticipated market demand and enabling revenue generation from product sales.
-
Expansion of the Symphony Cartridge Library with New Biomarkers: Beyond the initial IL-6 test for sepsis, Bluejay Diagnostics' Symphony platform is designed to accommodate a library of diagnostic cartridges. The company is developing additional biomarkers for the detection of other diseases, such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. The successful development and regulatory approval of these additional tests would diversify Bluejay's product offerings and create new revenue streams by expanding the platform's diagnostic utility into broader critical care areas.
AI Analysis | Feedback
Share Issuance
- Bluejay Diagnostics raised $3.5 million through a public offering in January 2024.
- The company raised an additional $8.57 million through a public offering in June 2024.
- On October 10, 2025, Bluejay Diagnostics completed a private placement, generating $4.5 million in gross proceeds from the sale of common stock and warrants, with proceeds intended to fund FDA approval efforts, clinical studies, and research and development.
Inbound Investments
- Bluejay Diagnostics secured $1 million in Bridge Note Financing in May 2024.
- The company completed a $3.8 million warrant-inducement financing in April 2025.
- A $4.5 million private placement (PIPE financing) closed in October 2025.
Capital Expenditures
- Capital expenditures for the last 12 months were reported as -$1,352, indicating minimal new investment or net sales of property, plant, and equipment.
- Proceeds from the October 2025 private placement are intended to fund FDA approval efforts, clinical studies, research and development activities, and general working capital needs.
- The company plans to transfer the manufacturing of Symphony cartridges to an in-house facility for redevelopment, followed by a transfer to an FDA-registered Contract Manufacturing Organization. This indicates a primary focus on manufacturing scale-up and operational readiness in capital allocation.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Bluejay Diagnostics Stock Plummets 37% With 11-Day Losing Streak | 12/23/2025 | |
| 10-Day Sell-Off Sends Bluejay Diagnostics Stock Down 34% | 12/20/2025 | |
| Bluejay Diagnostics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to BJDX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.29 |
| Mkt Cap | 0.5 |
| Rev LTM | 1,423 |
| Op Inc LTM | 24 |
| FCF LTM | -13 |
| FCF 3Y Avg | 13 |
| CFO LTM | 50 |
| CFO 3Y Avg | 98 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.0% |
| Rev Chg 3Y Avg | -0.1% |
| Rev Chg Q | 3.7% |
| QoQ Delta Rev Chg LTM | 0.9% |
| Op Inc Chg LTM | 10.5% |
| Op Inc Chg 3Y Avg | 3.9% |
| Op Mgn LTM | 2.0% |
| Op Mgn 3Y Avg | 4.1% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 3.9% |
| CFO/Rev 3Y Avg | 5.4% |
| FCF/Rev LTM | -3.0% |
| FCF/Rev 3Y Avg | -0.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 3.6 |
| P/Op Inc | 7.1 |
| P/EBIT | -0.5 |
| P/E | -0.4 |
| P/CFO | 3.7 |
| Total Yield | -85.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -1.1% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.9% |
| 3M Rtn | -33.3% |
| 6M Rtn | -44.7% |
| 12M Rtn | -43.2% |
| 3Y Rtn | -70.8% |
| 1M Excs Rtn | -17.6% |
| 3M Excs Rtn | -36.9% |
| 6M Excs Rtn | -51.5% |
| 12M Excs Rtn | -75.0% |
| 3Y Excs Rtn | -144.3% |
Price Behavior
| Market Price | $1.90 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/10/2021 | |
| Distance from 52W High | -86.4% | |
| 50 Days | 200 Days | |
| DMA Price | $2.00 | $4.75 |
| DMA Trend | down | down |
| Distance from DMA | -5.2% | -60.1% |
| 3M | 1YR | |
| Volatility | 85.6% | 135.1% |
| Downside Capture | 1.86 | 0.38 |
| Upside Capture | 22.14 | -94.52 |
| Correlation (SPY) | 29.7% | 7.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.30 | 1.81 | 1.91 | 0.62 | 0.08 | 0.28 |
| Up Beta | 2.53 | 7.56 | 6.52 | 2.48 | -0.79 | 0.33 |
| Down Beta | 1.15 | 0.83 | 2.50 | 4.27 | 2.62 | 2.38 |
| Up Capture | -33% | -44% | 1% | -146% | -48% | -8% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 16 | 26 | 42 | 95 | 291 |
| Down Capture | 19% | 243% | 138% | 33% | 80% | 100% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 24 | 35 | 80 | 143 | 440 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BJDX | |
|---|---|---|---|---|
| BJDX | -72.1% | 134.9% | -0.40 | - |
| Sector ETF (XLV) | 7.7% | 15.8% | 0.28 | 3.9% |
| Equity (SPY) | 34.0% | 12.6% | 2.05 | 8.0% |
| Gold (GLD) | 42.9% | 27.2% | 1.29 | -7.4% |
| Commodities (DBC) | 46.4% | 18.0% | 1.97 | -4.2% |
| Real Estate (VNQ) | 14.2% | 13.3% | 0.74 | 1.5% |
| Bitcoin (BTCUSD) | -16.6% | 42.1% | -0.32 | 10.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BJDX | |
|---|---|---|---|---|
| BJDX | -89.6% | 155.2% | -0.95 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 6.6% |
| Equity (SPY) | 12.7% | 17.1% | 0.58 | 6.9% |
| Gold (GLD) | 21.2% | 17.8% | 0.97 | -4.3% |
| Commodities (DBC) | 14.5% | 19.1% | 0.62 | 3.1% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 4.0% |
| Bitcoin (BTCUSD) | 7.0% | 56.3% | 0.34 | 4.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BJDX | |
|---|---|---|---|---|
| BJDX | -67.7% | 155.2% | -0.95 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 6.6% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 6.9% |
| Gold (GLD) | 13.9% | 15.9% | 0.73 | -4.3% |
| Commodities (DBC) | 10.1% | 17.8% | 0.47 | 3.1% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 4.0% |
| Bitcoin (BTCUSD) | 68.3% | 66.9% | 1.07 | 4.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/6/2026 | -2.1% | 4.2% | 8.4% |
| 11/9/2023 | 5.7% | 5.7% | -1.9% |
| 8/16/2023 | 0.9% | -6.0% | -55.3% |
| 3/20/2023 | -16.4% | -18.3% | -34.0% |
| 11/8/2022 | -8.0% | -8.3% | -32.9% |
| 7/26/2022 | 13.3% | -10.8% | -13.3% |
| 3/10/2022 | -6.5% | 15.6% | 6.5% |
| 12/16/2021 | -4.4% | 4.8% | -2.2% |
| SUMMARY STATS | |||
| # Positive | 3 | 4 | 2 |
| # Negative | 5 | 4 | 6 |
| Median Positive | 5.7% | 5.2% | 7.5% |
| Median Negative | -6.5% | -9.6% | -23.1% |
| Max Positive | 13.3% | 15.6% | 8.4% |
| Max Negative | -16.4% | -18.3% | -55.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/06/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/20/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2027 Capital Raising | 20.00 Mil | ||||||
Prior: Q3 2023 Earnings Reported 11/9/2023
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2024 Regulatory Submission | Affirmed | Guidance: 0 for 2024 | |||||
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.